KEY TAKEAWAYS
- The study aimed to elucidate the impact of the sCD150 isoform on the constitutive activation of CD150+ cells, utilizing an ELISA assay to assess its levels in CLL patients.
- Researchers concluded that the active secretion of sCD150 by CLL B cells represents a noteworthy factor contributing to the clinicopathologic variability in CLL patients.
SLAMF1/CD150 plays a crucial role in chronic lymphocytic leukemia (CLL) B cell signaling, engaging in homophilic binding or interaction with the soluble CD150 isoform (sCD150). While sCD150 expression has been confirmed at mRNA and protein levels ex vivo, its significance in the plasma of CLL patients remains unclear concerning CD150+ cell activation.
I, Gordiienko, and her team aimed to develop a specific ELISA assay for sCD150 and assess its levels in CLL patients’ plasma, particularly those with varying CD150 expression on B cells.
They performed an inclusive analysis using blood plasma samples and peripheral blood mononuclear cells obtained from 40 previously untreated CLL patients. The methodology involved utilizing an ELISA method, an ex vivo drug sensitivity assay, and a cell viability assay to comprehensively evaluate the biological characteristics and responses within the CLL patient cohort.
The sCD150 isoform was detected in all analyzed plasma samples from CLL patients, exhibiting varying levels independent of the cell surface CD150 expression status of B cells and sCD150 mRNA expression. In CLL cases characterized by low cell surface CD150 expression on B cells, notably high levels of sCD150 were observed in blood plasma, contrasting with CLL cases featuring high CD150 expression on B cells. The observed elevated levels of sCD150 in blood plasma were significantly associated with enhanced sensitivity of malignant B cells to cyclophosphamide and bendamustine.
The study concluded that the active secretion of the sCD150 isoform by CLL B cells, leading to its accumulation in blood plasma, emerges as a noteworthy contributor to the clinicopathologic variability in CLL.
Source: https://pubmed.ncbi.nlm.nih.gov/38328844/
Gordiienko I, Scherbina V, Shlapatska L. (2024). SOLUBLE CD150 ISOFORM LEVEL IN PLASMA OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. Exp Oncol. 2024 Feb 3;45(4):457-462. doi: 10.15407/exp-oncology.2023.04.457. PMID: 38328844.
